Ultragenyx Pharmaceutical stock reacts to shifting sentiment Ultragenyx Pharmaceutical (RARE) has been quietly recalibrating investor expectations, with the stock up about 10% over the past month even ...
The FDA has approved DAYBUE STIX, a new powder option for Rett syndrome that grows royalty streams. The post Neuren ...
Irish Examiner on MSN
Profits at Johnson & Johnson's Cork facility decrease by 35%
Revenues at the main Irish arm of the pharmaceutical giant fell by 2%, from €11.6bn to €11.39bn, last year ...
The next few years of projected revenues in the pharma space have more holes in them than industry CEOs’ favorite golf ...
Can the immune system cure cancer? Dr. Patrick Soon-Shiong discusses a paradigm shift using NK cells to treat tumors without ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback